Cantor Fitzgerald reiterates 'Overweight' on Theratechnologies Inc. (THTX) following updates

Cantor Fitzgerald analyst Louis Chen reiterated an Overweight rating and $9.00 price target on Theratechnologies Inc. (NASDAQ: THTX) after the company made several positive announcements (financial guidance and business updates) that support the firm's investment thesis on the stock.

The analyst commented, "THTX announced that it expects to meet its previously announced financial guidance and report ~$80MM in top line revenues for 2022 or ~15% YoY growth in its commercial business. THTX also released its FY2023 financial guidance, for the first time, and updated the key objectives for its operating plan, including the development pathway for TH1902 (peptide drug conjugate “PDC” for the treatment of sortilin-expressing cancers), and visibility to positive cash flow from operations in 2023+. Finally, THTX has built out a dedicated in-house sales force, removing its reliance on external contract organizations."

For an analyst ratings summary and ratings history on Theratechnologies Inc. click here. For more ratings news on Theratechnologies Inc. click here.

Shares of Theratechnologies Inc. closed at $0.98 yesterday.

You May Also Be Interested In

• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)